Please login to the form below

Not currently logged in

BTK inhibitor

This page shows the latest BTK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Sanofi gains access to antibody tech with Kymab acquisition

Sanofi gains access to antibody tech with Kymab acquisition

Principia’s lead candidate and focus of the acquisition was Bruton tyrosine kinase (BTK) inhibitor ‘168, currently in development for the treatment of multiple sclerosis (MS). ... In 2017, Sanofi signed a deal with Principia for exclusive rights to

Latest news

More from news
Approximately 2 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica. ... Its BTK inhibitor zanubrutinib was granted Fast Track designation by the US FDA in

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Deal Watch January 2018

    Collaboration, licence. 380. Jiangsu Hengrui Medicine/TG Therapeutics. BTK inhibitor programme, incl lead candidate TG-1701 (p1) and another BTK inhibitor (pc). ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Deal Watch November 2015 Deal Watch November 2015

    Overall 2015 has been a very busy year for Hanmi which in March closed a $690m deal with Lilly for a phase 1 BTK-inhibitor in autoimmune indications and also in ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration, licence. Sotagliflozin, p3 oral

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....